Cover Image

ESG‐1‐60 and ESG‐1‐61: Novel dopamine D3 receptor‐preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Omar Soler‐Cedeño, Bradley M. Keegan, Hannah Alton, Guo‐Hua Bi, Emily Linz, Caleb D. Vogt, Emma S. Gogarnoiu, Lei Shi, Amy Hauck Newman, Zheng‐Xiong Xi
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dual DAT and sigma receptor inhibitors attenuate cocaine effects on nucleus accumbens dopamine dynamics in rats
by: Melinda Hersey, et al.
Published: (2024)

The dopamine D2 receptors antagonist Veralipride inhibits carbonic anhydrases: solution and crystallographic insights on human isoforms
by: Andrea Angeli, et al.
Published: (2024)

Comparative analysis of computational approaches for predicting Transthyretin (TTR) transcription activators and human dopamine D1 receptor antagonists
by: Ivanova, Mariya L., et al.
Published: (2025)

Intravenous cocaine priming reinstates cocaine-induced conditioned place preference
by: Andrés S. Lombas
Published: (2007)

Corporate risk‐taking, economic policy uncertainty and ESG performance: International evidence
by: Chai‐Aun Ooi, et al.
Published: (2024)

The ESG Backlash and the Demand for ESG Mutual Funds
by: Quinn Curtis
Published: (2025)

Use of dopamine antagonists on induced spawning of Indian major carps
by: Singh, K., et al.
Published: (1996)

Oral pre‐ and early postnatal cannabis exposure disinhibits ventral tegmental area dopamine neuron activity but does not influence cocaine preference in offspring in mice
by: Colleen S. Peterson, et al.
Published: (2024)

EulerESG: Automating ESG Disclosure Analysis with LLMs
by: Ding, Yi, et al.
Published: (2025)

Ischemic stroke risk in patients with dopamine agonist‐treated hyperprolactinemia
by: Amit Akirov, et al.
Published: (2025)

ESG Controversies and Firm Value: Moderating Role of ESG Performance*
by: Hyeong Joon Kim, et al.
Published: (2025)

ESG Reporting, ESG Contracting, and Executive Compensation: International Evidence
by: Weiqing Chen, et al.
Published: (2025)

Research progress on the roles of dopamine and dopamine receptors in digestive system diseases
by: Xianmin Lu, et al.
Published: (2024)

The role of β‐adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β‐adrenergic receptor agonists and antagonists protect the heart?
by: Leonid N. Maslov, et al.
Published: (2024)

Maternal immune activation is associated with a lower number of dopamine receptor 3-expressing granulocytes with no alterations in cocaine reward, resistance to extinction or cue-induced reinstatement
by: Santos-Toscano, R., et al.
Published: (2020)

ESG-Bench: Benchmarking Long-Context ESG Reports for Hallucination Mitigation
by: Sun, Siqi, et al.
Published: (2026)

Developing an ESG-Oriented Large Language Model through ESG Practices
by: Assis, Gabriel, et al.
Published: (2026)

Corporate ESG Washing and ESG Rating Divergence: Evidence From China
by: Hanwen Chen, et al.
Published: (2025)

An Austrian Take on ESG
by: Henrique Schneider
Published: (2021)

Walking the Tightrope of Governance and Sustainability: Strategic ESG Disclosure Under Regulatory Environment in Emerging Markets
by: Timothy Masuni Nagriwum, et al.
Published: (2026)

Optimal Matrix-Mimetic Tensor Algebras via Variable Projection
by: Newman, Elizabeth, et al.
Published: (2024)

Projected Tensor-Tensor Products for Efficient Computation of Optimal Multiway Data Representations
by: Keegan, Katherine, et al.
Published: (2024)

ESG controversies and corporate performance: The moderating effect of governance mechanisms and ESG practices
by: Ahmed A. Elamer, et al.
Published: (2024)

Is ESG Transparency the Fruit of Corporate Digitalization: Strategic Pathways to Enhanced ESG Disclosure?
by: Yanqi Sun, et al.
Published: (2025)

ESG Performance and Dividend Payout: The Moderating Role of ESG Controversies and Legal Systems
by: Satish Kumar, et al.
Published: (2025)

Start where you are: ESG for companies of all sizes : the importance of ESG for SMEs
by: International Labour Organization
Published: (2026)

Navigating the ESG alphabet soup: a concise dictionary of the ESG acronym landscape
Published: (2025)

Measuring Sustainability Under Uncertainty: Introducing Net ESG (N‐ESG) Performance
by: Serdar Ongan, et al.
Published: (2025)

ESG Rating Disagreement and the Size of the Investable Universe Under ESG Consensus Rules
by: Christian Lohmann, et al.
Published: (2025)

Does ESG performance impact value and risk‐taking by commercial banks? Evidence from emerging market economies
by: Mayank Gangwani, et al.
Published: (2024)

GLP‐1 receptor agonists not associated with increased suicidality
Published: (2024)

Inhibitory effects of the selective μ‐opioid receptor antagonist UD‐030 on methamphetamine‐induced conditioned place preference
by: Soichiro Ide, et al.
Published: (2024)

Sex‐based disparities in dopamine agonist response in patients with restless legs syndrome
by: Maria P. Mogavero, et al.
Published: (2024)

ESG-FTSE: A corpus of news articles with ESG relevance labels and use cases
by: Pavlova, Mariya, et al.
Published: (2024)

Does ESG Report Tone Influence ESG Rating Divergence? Evidence From China
by: Yanmei Luo, et al.
Published: (2025)

ESG , ESG Disagreement and Maturity Mismatch Between Investment and Financing: Evidence From China
by: Ye Tao, et al.
Published: (2025)

Does ESG Reporting Matter for Shareholder Value?—Evidence on Mandatory ESG Regulations in India
by: Prasenjit Chakrabarti, et al.
Published: (2025)

Avoiding Harm by Doing Good. The Substantive Role of ESG Payments for Preventing ESG Misconduct
by: Emma García‐Meca, et al.
Published: (2025)

Environmental, Social, and Governance (ESG) and ESG Controversies: Opportunities or Challenges in Achieving Firm Efficiency?
by: Qian Long Kweh, et al.
Published: (2025)

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity
by: Takayuki Suzuki, et al.
Published: (2026)